DE69615685D1 - Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen - Google Patents

Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen

Info

Publication number
DE69615685D1
DE69615685D1 DE69615685T DE69615685T DE69615685D1 DE 69615685 D1 DE69615685 D1 DE 69615685D1 DE 69615685 T DE69615685 T DE 69615685T DE 69615685 T DE69615685 T DE 69615685T DE 69615685 D1 DE69615685 D1 DE 69615685D1
Authority
DE
Germany
Prior art keywords
pct
composition
hiv infections
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69615685T
Other languages
English (en)
Other versions
DE69615685T2 (de
Inventor
Jean-Claude Chermann
Contel Carole Le
Pascale Galea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of DE69615685D1 publication Critical patent/DE69615685D1/de
Application granted granted Critical
Publication of DE69615685T2 publication Critical patent/DE69615685T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69615685T 1995-06-30 1996-06-28 Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen Expired - Lifetime DE69615685T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9507914A FR2735984B1 (fr) 1995-06-30 1995-06-30 Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
PCT/FR1996/001006 WO1997002344A2 (fr) 1995-06-30 1996-06-28 Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv

Publications (2)

Publication Number Publication Date
DE69615685D1 true DE69615685D1 (de) 2001-11-08
DE69615685T2 DE69615685T2 (de) 2002-08-08

Family

ID=9480577

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69615685T Expired - Lifetime DE69615685T2 (de) 1995-06-30 1996-06-28 Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen

Country Status (13)

Country Link
US (1) US6113902A (de)
EP (1) EP0835309B1 (de)
JP (1) JP4036895B2 (de)
CN (1) CN1117148C (de)
AT (1) ATE206456T1 (de)
AU (1) AU6462396A (de)
CA (1) CA2223825A1 (de)
DE (1) DE69615685T2 (de)
DK (1) DK0835309T3 (de)
ES (1) ES2165510T3 (de)
FR (1) FR2735984B1 (de)
PT (1) PT835309E (de)
WO (1) WO1997002344A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
ATE466870T1 (de) * 2002-12-06 2010-05-15 Zhi Cheng Xiao Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
TW200846363A (en) * 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
EP2374470A1 (de) * 2010-04-08 2011-10-12 Beta Innov Therapeutische Anwendung von Protein Beta-2-M
EP3512551A4 (de) * 2016-09-16 2020-08-05 The Brigham and Women's Hospital, Inc. Blockade von wechselwirkungen des alpha-feto-proteins (aflp) mit beta2-mikroglobulin-assoziierten molekülen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK160944C (da) * 1986-01-16 1991-10-21 Novo Industri As Modificerede beta2-mikroglobuliner og farmaceutiske praeparater indeholdende disse
US5733550A (en) * 1990-05-10 1998-03-31 Dana-Farber Cancer Institute, Inc. Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin
FR2675508A1 (fr) * 1991-04-18 1992-10-23 Tm Innovation Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant.
GB9201023D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Vaccines
GB9214871D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Vaccines
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
GB9307371D0 (en) * 1993-04-08 1993-06-02 Walls Alan J Fusion proteins

Also Published As

Publication number Publication date
EP0835309B1 (de) 2001-10-04
ATE206456T1 (de) 2001-10-15
ES2165510T3 (es) 2002-03-16
CA2223825A1 (fr) 1997-01-23
FR2735984A1 (fr) 1997-01-03
DE69615685T2 (de) 2002-08-08
JPH11509407A (ja) 1999-08-24
PT835309E (pt) 2002-03-28
EP0835309A2 (de) 1998-04-15
WO1997002344A2 (fr) 1997-01-23
CN1193349A (zh) 1998-09-16
JP4036895B2 (ja) 2008-01-23
FR2735984B1 (fr) 1997-09-19
US6113902A (en) 2000-09-05
WO1997002344A3 (fr) 1997-03-06
AU6462396A (en) 1997-02-05
DK0835309T3 (da) 2002-12-02
CN1117148C (zh) 2003-08-06

Similar Documents

Publication Publication Date Title
ATE326236T1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
DE69131200T2 (de) Herpes simplex virus vp16 impfstoffe
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE211927T1 (de) Verfahren zur virusinaktivierung in gegenwart eines polyethers und eines agens
ATE206456T1 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ATE425187T1 (de) Materialien und methoden zur behandlung von hepatitis c
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
GR3034155T3 (en) Water-soluble epipodophyllotoxin derivatives, preparation method therefor, and use thereof as a drug and for treating cancer
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
DE60013326D1 (de) Verbindungen und verfahren zur behandlung von schmerz
WO2000063386A3 (en) Prevention, diagnosis and treatment of lyme disease
ATE201882T1 (de) Formulierung von energie
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
ATE401349T1 (de) Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen
RU2001106308A (ru) Способ лечения гнойных инфекций
RU93055681A (ru) Ингибиторы вич-протеазы, способ их получения, их использование в фармкомпозициях
EP1419784A3 (de) Proteasom-Impfstoffzusammensetzungen gegen Allergie, Krebs und Toxine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition